MOUNTAIN VIEW, Calif., April 6, 2016 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL) is pleased to report that UW Health, the system associated with the University of Wisconsin-Madison, is adding the i.v.STATION ONCO™, which provides robotic sterile compounding of oncology admixtures, to their pharmacy automation solutions. UW Health selected the Aesynt product, now part of Omnicell's product portfolio, for use in the drug distribution process at their main University Hospital as well as in three additional facilities in their health system. In addition, the hospital is updating their existing ROBOT-Rx® automated medication dispensing robot and upgrading their AcuDose-Rx® automated dispensing cabinets. These and other products from Aesynt have recently been added to the Omnicell portfolio, expanding Omnicell's ability to support all key pharmacy distribution models, described as follows:
- Centralized: Most medications are distributed from a central location, and pharmacy staff help prepare and distribute medications by patient to nursing units.
- Decentralized: Most medications are stored in automated dispensing cabinets near patient care areas where nurses dispense them by patient.
- Hybrid: This approach combines aspects of both centralized and decentralized dispensing models based on the specific capabilities of the pharmacy.
Omnicell is offering Aesynt's leading sterile IV compounding technology, which includes the i.v.STATION ONCO being implemented at UW Health to handle oncology and other hazardous preparations. IV automation offers a safe, accurate and cost-effective solution for compounding and dispensing IV admixtures. Adding this automation enables the health care system to streamline compounding processes, helping to simplify workflows, minimize employee exposure to potentially dangerous materials, and support improved care for oncology patients by eliminating medication errors. This IV automation also helps to significantly improve efficiency in drug delivery and allows clinicians to spend more time on patient-facing activities.
In addition to the new IV technology, the main University Hospital has upgraded their medication automation cabinets throughout the hospital.
"Our plans for IV automation were first envisioned during reconstruction of our cancer center last year," said Steve Rough, director of pharmacy at UW Hospitals and Clinics. "The goal is to keep both patients and employees safe, and to minimize medication waste."
"The hybrid-pharmacy approach in our health system is designed to support existing demand while ensuring the best use of our clinical staff," said Brad Ludwig, assistant director of pharmacy at UW Hospital and Clinics. "We are working with members at all levels of our health system in achieving a safe and efficient medication delivery model."
"We are pleased to work with long-time Aesynt partners at UW Health to continue offering tailored medication distribution solutions and processes to their facilities," said J. Christopher Drew, president, North American Automation and Analytics for Omnicell. "By expanding our offering of pharmacy products for centralized and decentralized distribution, we are now able to provide our customers with increased customization options along the full spectrum of medication and supply automation products throughout the health care continuum."
About UW Health
UW Health is the integrated health system of the University of Wisconsin-Madison serving more than 600,000 patients each year in the Upper Midwest and beyond with 1,400 physicians and 16,500 staff at six hospitals and 80 outpatient sites. UW Health is governed by the UW Hospitals and Clinics Authority and partners with UW School of Medicine and Public Health to fulfill their patient care, research, education and community service missions.
Since 1992, Omnicell (NASDAQ: OMCL) has been creating innovative solutions to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for medication and supply management across the entire health care continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient's home.
Approximately 4,000 customers worldwide use Omnicell automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety. The recent acquisition of Aesynt adds distinct capabilities, particularly in central pharmacy and IV robotics, creating the broadest medication management product portfolio in the industry.
The Omnicell SureMed® solution provides innovative medication adherence packaging to help reduce costly hospital readmissions. In addition, these solutions enable approximately 7,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.
For more information about Omnicell, Inc. please visit www.omnicell.com.
- All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company's external website, omnicell.com.
- Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
- All other brand or product names may be trademarks or registered trademarks of their respective companies.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/uw-health-adds-new-iv-automation-capabilities-and-solutions-to-enhance-hybrid-drug-distribution-process-300246961.html
SOURCE Omnicell, Inc.